Gain insights on key topics around artificial intelligence. Learn tips on boosting your knowledge and use of generative AI, developing and implementing an AI governance strategy, integrating AI into the legal department, meeting ethical obligations, protecting your organization's intellectual property, and addressing AI issues in vendor contracts.
This blog explores physician recapitalization transactions and how complex they are and their myriad issues. At Foley, in our representation of both investors in, and sellers of, physician practices, we note how often tax issues become gating items that drive the structural aspects of the transaction.
Foley & Lardner’s Top Trends for 2024 publication unpacks key developments in an uncertain regulatory landscape.
Since its inception in 1992, the 340B Drug Pricing Program (340B Program) has provided eligible health care providers (covered entities) access to significant discounts on the cost of outpatient pharmaceuticals from participating manufacturers.
Over the past 15 years, the 340B Program’s size and scope has expanded due to actions by Congress and the federal Health Resources and Services Administration (HRSA). This article provides an overview of the program's current state.
This Privacy Capability Maturity Model provides a detailed maturity model for all aspects of an organization’s privacy program, including its use of Artificial Intelligence (AI) and Machine Learning (ML) using personal information.
It seeks to gauge program capability across a variety of program elements, taking a “big picture” view on an organization’s readiness to comply with these requirements.
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding pharmaceutical advertising across a range of jurisdictions.
The Schrems II decision invalidated the US/EU Privacy Shield program for data transfers, but a replacement has not yet been negotiated for US companies. Schrems II will impact US data transfers eventually, but in the meantime US companies can prepare for the changes.
This article with its sample delegation of authority (DOA) form will assist in-house counsel who are struggling with issues related to signing authority, staff approval limits, and information passing.
Learn about the significant implications (for data users and holders) of the Data Act proposed by the European Commission in February 2022, regarding who can use and access data generated by connected devices.
This resource provided by Foley & Lardner LLP covers the DOJ’s announcement on February 6th of their withdrawal of the 2011 Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program (2011 ACO Statement) in addition to two other health care antitrust policy statements.